Satellos Bioscience Inc. News Releases

Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

Wed, 20 Sep 2023 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will participate in the Cantor Fitzgerald Global Healthcare Conference 2023 taking place September 26 - 28 in New York City.Mr. Frank Gleeson, President and CEO of Satellos, will...

Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

Thu, 07 Sep 2023 17:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has entered into an agreement with ICP Securities Inc. ("ICP"), a dealer member in good standing with the Canadian Investment Regulatory Organization, to provide market making services for the...

Satellos Expands Leadership Team with New CFO Appointment

Tue, 05 Sep 2023 07:30:00 -0400

Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX.Current CFO, Warren Whitehead, CPA, CMA, transitions to Head of Corporate Strategy to focus on strengthening and expanding collaborations and partnerships.Satellos is advancing a potentially first-in-class small molecule drug candidate to clinical trials for Duchenne muscular dystrophy.Toronto, Ontario--(Newsfile Corp. - September 5,...

Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

Tue, 29 Aug 2023 07:00:00 -0400

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers and Duchenne muscular dystrophy patients Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy

Wed, 02 Aug 2023 07:00:00 -0400

Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with Duchenne Toronto, Ontario--(Newsfile Corp. - August 2, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating muscle diseases and disorders, announced today that that U.S. Food and Drug Administration (FDA) has...

Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan

Fri, 30 Jun 2023 07:43:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the results of its annual general meeting of shareholders held virtually on June 29, 2023 (the "Meeting"), as well as the adoption of amendments to the Company's Stock Option Plan.A total of 34,607,323 common shares were voted in...

Satellos Bioscience Announces Appointment of Chief Medical Officer

Wed, 07 Jun 2023 07:01:00 -0400

Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023 Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Alan K. Jacobs, MD as Chief Medical Officer (CMO) of the Company, effective June 7, 2023."Dr. Jacobs is an accomplished and experienced clinical development...

Satellos Bioscience Announces Grant of Stock Options

Thu, 01 Jun 2023 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors (the "Board") has approved grants of stock options (the "Stock Options") pursuant to the terms of the Company's Stock Option Plan. A total of 5,732,797 Stock Options have been awarded to directors, officers,...

Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights

Tue, 30 May 2023 18:36:00 -0400

- $55 million equity financing closed- Resourced to advance lead drug candidate into clinical trialsToronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three months ending March 31, 2023. All references to...

Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy

Wed, 17 May 2023 09:24:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that it has closed an equity offering, issuing a total of 110 million equity securities for gross proceeds of $55 million (the "Offering"). The Offering included participation from funds managed by Avidity Partners, Qiming Venture...